Hormone Testing for a 51-Year-Old Woman
For a 51-year-old woman, order FSH, estradiol (E2), TSH, and prolactin as the core hormone panel, with additional testosterone and AMH if menstrual irregularities or specific symptoms are present.
Core Laboratory Tests
At age 51, a woman is likely perimenopausal or early postmenopausal. The essential hormone tests depend on her clinical presentation:
Basic Panel (All Women)
FSH (Follicle-Stimulating Hormone): Draw on days 3-6 of menstrual cycle if still cycling 1. FSH >35 IU/L with low estradiol (<20 pg/mL) indicates menopause 2. For women with irregular cycles or amenorrhea, timing is less critical but ideally obtain in early morning 1.
Estradiol (E2): Same timing as FSH. Levels <50 pg/mL suggest perimenopause; <20 pg/mL indicates postmenopause 1. This helps distinguish menopausal status and guides hormone therapy decisions 3.
TSH and Free T4: Essential to exclude thyroid dysfunction, which commonly mimics or coexists with menopausal symptoms 2, 1. Thyroid disorders are frequent in this age group and affect interpretation of other hormones.
Prolactin: Morning resting level (not after stress or breast examination). Elevated levels (>20 μg/L) require exclusion of pituitary adenoma or hypothyroidism 2. Critical for evaluating amenorrhea or galactorrhea.
Additional Tests Based on Clinical Features
If menstrual irregularities present:
LH (Luteinizing Hormone): Obtain with FSH. LH/FSH ratio >2 suggests PCOS even at this age 2. LH >11 IU/L with elevated FSH confirms menopause 2.
Progesterone: Mid-luteal phase (if cycles identifiable). Levels <6 nmol/L indicate anovulation 2.
If hirsutism, acne, or androgenic symptoms:
Total Testosterone: Early morning, days 3-6 of cycle if menstruating. Initial screening test per Endocrine Society guidelines 4. Levels >2.5 nmol/L are abnormal 2.
DHEA-S: To exclude adrenal source of androgens. Age-specific ranges apply (age 30-39: >2700 ng/mL abnormal) 2.
17-hydroxyprogesterone: Early morning, follicular phase, only if high suspicion for congenital adrenal hyperplasia (family history, high-risk ethnicity) 4.
If assessing ovarian reserve or fertility concerns:
- AMH (Anti-Müllerian Hormone): Excellent predictor of time to menopause. AMH <10 pg/mL indicates 51-79% probability of menopause within 12 months at this age; AMH >100 pg/mL indicates 90% probability of NOT reaching menopause within 12 months 5. More predictive than FSH for timing of final menstrual period 5.
Practical Testing Algorithm
- Start with FSH, E2, TSH, prolactin for all women age 51 requesting hormone evaluation
- Add LH and progesterone if menstrual cycles are irregular (>35 days apart or <23 days) 2
- Add testosterone and DHEA-S if signs of androgen excess (hirsutism, acne, male-pattern hair loss) 4
- Add AMH if patient wants to know timing of menopause or has fertility concerns 5
Critical Timing and Technical Considerations
- Draw all tests in early morning (7-9 AM) for consistency, especially testosterone and 17-hydroxyprogesterone 4, 1
- For cycling women: Days 3-6 of cycle for FSH, LH, testosterone; mid-luteal phase for progesterone 2
- For amenorrheic women: Any time acceptable, but document timing 1
- Testosterone assays: Use specialty laboratory with validated assays (mass spectrometry preferred) rather than automated immunoassays, which are unreliable in women 4. If total testosterone normal but clinical suspicion high, add free testosterone from reliable lab 4.
Common Pitfalls to Avoid
- Don't rely on single FSH measurement: FSH fluctuates significantly in perimenopause. Elevated FSH with normal E2 may not indicate menopause 1.
- Don't check LH/FSH ratio routinely: Only 35-44% sensitive for PCOS diagnosis despite being commonly ordered 6. Total testosterone is superior (70% sensitivity) 6.
- Don't skip thyroid testing: Thyroid dysfunction mimics menopausal symptoms and affects interpretation of reproductive hormones 2, 1.
- Avoid post-stress prolactin: Must be morning, resting sample. Post-exercise, post-coital, or post-breast exam samples are unreliable 2.
The evidence strongly supports a targeted approach based on symptoms rather than comprehensive "hormone panels" that include unnecessary tests 1, 3. At age 51, the primary goal is determining menopausal status and excluding pathology, not comprehensive endocrine screening.